Patents by Inventor Thomas Borchardt

Thomas Borchardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190176116
    Abstract: A system for fabricating microparticles useful for example in managing invasive species is provided. The system provides a nozzle for atomizing liquefied droplet material which is then suspended in a cyclonic separator receiving refrigerated gas until the droplets can solidify. In this way small droplets (less than 100 ?m) can be readily fabricated in bulk without clumping and aggregating.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 13, 2019
    Inventors: Thomas J. Zolper, Jon J. Amberg, Nathan L. Klaassen, Carter J. Rowley, Karl Chic, Brad Borchardt
  • Patent number: 10286137
    Abstract: An oxygenator module for gas exchange between blood and a gas in an extracorporeal lung support system, with several layers of semipermeable, gas-perfusable hollow fibers, wherein the hollow fibers of one of the layers are oriented at an angle of rotation about a central longitudinal axis of the oxygenator module with respect to the hollow fibers of another one of the layers, and with a potting which extends along the central longitudinal axis and in which the hollow fibers are fixed, wherein the potting defines a cavity that extends along the central longitudinal axis and in which the hollow fibers are arranged and which is blood-perfusable in the direction of the central longitudinal axis, wherein the potting has an essentially circular inner sheath surface that limits the cavity radially outward; as well as a method for producing the oxygenator module.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: May 14, 2019
    Assignee: Novalung GmbH
    Inventors: Andreas Maurer, Josef Bogenschuetz, Thomas Schmitz-Rode, Ulrich Steinseifer, Jutta Arens, Georg Wagner, Ralf Borchardt, Peter Christian Schlanstein
  • Patent number: 8771835
    Abstract: Bio-degradable, high-barrier packaging materials and methods for production are provided. The present high-barrier packaging materials include a substrate having a print side and a back side, a coating having nano pigments on the print side and a metalized film applied to the back side with a binding layer. Preferably, at least one of the metalized film and the binding layer includes polylactic acid. Moreover, the back side preferably also includes a polylactic acid heat seal layer.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: July 8, 2014
    Assignee: NewPage Wisconsin System, Inc.
    Inventors: Gopal Iyengar, Thomas Borchardt, Gerald Lowe
  • Patent number: 8362013
    Abstract: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: January 29, 2013
    Assignee: AbbVie Inc.
    Inventors: Thomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G. Z. Zhang, Deliang Zhou
  • Publication number: 20120028908
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Application
    Filed: October 1, 2011
    Publication date: February 2, 2012
    Applicant: Abbott Laboratories
    Inventors: Shekhar VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Patent number: 8034926
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 11, 2011
    Assignee: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Patent number: 8030326
    Abstract: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 4, 2011
    Assignee: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Publication number: 20110009325
    Abstract: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Abbott Laboratories
    Inventors: SHEKHAR VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Publication number: 20110009618
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Publication number: 20100305125
    Abstract: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 2, 2010
    Inventors: Thomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G.Z. Zhang, Deliang Zhou
  • Patent number: 7820812
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: October 26, 2010
    Assignee: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Patent number: 7812032
    Abstract: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: October 12, 2010
    Assignee: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Publication number: 20100178523
    Abstract: Bio-degradable, high-barrier packaging materials and methods for production are provided. The present high-barrier packaging materials include a substrate having a print side and a back side, a coating having nano pigments on the print side and a metalized film applied to the back side with a binding layer. Preferably, at least one of the metalized film and the binding layer includes polylactic acid. Moreover, the back side preferably also includes a polylactic acid heat seal layer.
    Type: Application
    Filed: June 6, 2008
    Publication date: July 15, 2010
    Inventors: Gopal Iyengar, Thomas Borchardt, Gerald Lowe
  • Publication number: 20080091008
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Application
    Filed: July 23, 2007
    Publication date: April 17, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Publication number: 20080085880
    Abstract: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate.
    Type: Application
    Filed: July 23, 2007
    Publication date: April 10, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Publication number: 20080058528
    Abstract: A process for making (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile and salts thereof, and intermediates used in the process are disclosed.
    Type: Application
    Filed: July 19, 2007
    Publication date: March 6, 2008
    Inventors: Todd McDermott, Seble Wagaw, Kenneth Engstrom, Jorge Gandarilla, Albert Kruger, Michael Rozema, Michael Fickes, Steven Wittenberger, Lakshmi Bhagavatula, Thomas Borchardt
  • Publication number: 20070087212
    Abstract: A multi-layer, high barrier packaging lid material is adapted for releasably sealing to a plurality of containers including a first container comprised of one polymer and a second container comprised of another polymer. The packaging lid material comprises a paper base with an internal wet strength agent and an anti-wicking agent and having interior and exterior surfaces. A polymer oxygen barrier layer is bonded on the interior surface of the base. A tie layer is on the barrier layer, and a seal-peel layer is on the tie layer. The seal-peel layer is comprised of a blend of a first polymer and a second polymer. When the lid material is heat sealed to a first container the first polymer in the seal-peel layer bonds with the first container while the second polymer in said seal-peel layer functions as a contaminant to provide easy peeling.
    Type: Application
    Filed: December 15, 2006
    Publication date: April 19, 2007
    Inventors: Gopal Iyengar, Thomas Borchardt
  • Publication number: 20050267302
    Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.
    Type: Application
    Filed: December 4, 2003
    Publication date: December 1, 2005
    Applicant: G.D. Searle & Co.
    Inventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn Stahl, Joseph Wieczorek, Chris Yan
  • Publication number: 20050261261
    Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.
    Type: Application
    Filed: February 7, 2005
    Publication date: November 24, 2005
    Applicant: Pharmacia Corporation
    Inventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn Stahl, Joseph Wieczorek, Chris Yan
  • Publication number: 20050159594
    Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.
    Type: Application
    Filed: July 16, 2004
    Publication date: July 21, 2005
    Applicant: Pharmacia Corporation
    Inventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn L. Stahl, Joseph Wieczorek, Chris Yan